View in EDS

Safety considerations for cereblon-recruiting targeted protein degraders.

Saved in:
Bibliographic Details
Title: Safety considerations for cereblon-recruiting targeted protein degraders.
Authors: Garside H; ApconiX Ltd. Alderley Park, Macclesfield, UK., Aslamkhan A; Nonclinical Drug Safety, Merck & Co., Inc., West Point, PA, USA., Daniels DL; Foghorn Therapeutics, Cambridge, MA, USA., Datta K; Nonclinical Safety, Bristol Myers Squibb, New Brunswick, NJ, USA.; Nonclinical Drug Safety, Merck & Co., Inc., West Point, PA, USA., Egebjerg M; Safety Pharmacology & Early Toxicology, Novo Nordisk A/S, Måløv, Denmark., Hukkanen RR; Translational Safety & Risk Sciences, Amgen Research, Amgen Inc, Cambridge, MA, USA., Jones LH; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Ketter N; Non-clinical Safety Science, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany., Lahoti TS; Drug Safety Research & Evaluation, Takeda Development Center Americas, Inc., Cambridge, MA, USA.; Development Sciences, Atrium Therapeutics, San Diego, CA, USA., Loberg LI; Emerging Therapeutic Platforms, AbbVie, Inc., North Chicago, IL, USA., Messmer D; Nurix Therapeutics, San Francisco, CA, USA., O'Lone R; Health & Environmental Sciences Institute (HESI), Washington, DC, USA., Pastoor T; Oerth Bio, Durham, NC, USA., Pavkovic M; Preclinical Development, Pharma R&D, Bayer AG, Wuppertal, Germany., Pereira Mouriès L; Health & Environmental Sciences Institute (HESI), Washington, DC, USA., Rankovic Z; Institute of Cancer Research, London, Sutton, UK., Rengarajan A; Nonclinical Drug Safety, Merck & Co., Inc., West Point, PA, USA., Vargesson N; Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, UK., Vicart A; Preclinical Safety, Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Wange RL; Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.; Aclairo Pharmaceutical, Development Group, Inc., Sterling, VA, USA., Yanochko-Hoffman G; Preclinical Sciences & Translational Safety, Johnson & Johnson, San Diego, CA, USA., Roberts R; ApconiX Ltd. Alderley Park, Macclesfield, UK. ruth.roberts@apconix.com.; School of Biosciences, University of Birmingham, Edgbaston, UK. ruth.roberts@apconix.com., Sidaway J; ApconiX Ltd. Alderley Park, Macclesfield, UK.
Source: Nature reviews. Drug discovery [Nat Rev Drug Discov] 2026 Apr 20. Date of Electronic Publication: 2026 Apr 20.
Publication Type: Journal Article; Review
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101124171 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-1784 (Electronic) Linking ISSN: 14741776 NLM ISO Abbreviation: Nat Rev Drug Discov Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42009768
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety considerations for cereblon-recruiting targeted protein degraders.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Garside+H%22">Garside H</searchLink>; ApconiX Ltd. Alderley Park, Macclesfield, UK.<br /><searchLink fieldCode="AU" term="%22Aslamkhan+A%22">Aslamkhan A</searchLink>; Nonclinical Drug Safety, Merck & Co., Inc., West Point, PA, USA.<br /><searchLink fieldCode="AU" term="%22Daniels+DL%22">Daniels DL</searchLink>; Foghorn Therapeutics, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Datta+K%22">Datta K</searchLink>; Nonclinical Safety, Bristol Myers Squibb, New Brunswick, NJ, USA.; Nonclinical Drug Safety, Merck & Co., Inc., West Point, PA, USA.<br /><searchLink fieldCode="AU" term="%22Egebjerg+M%22">Egebjerg M</searchLink>; Safety Pharmacology & Early Toxicology, Novo Nordisk A/S, Måløv, Denmark.<br /><searchLink fieldCode="AU" term="%22Hukkanen+RR%22">Hukkanen RR</searchLink>; Translational Safety & Risk Sciences, Amgen Research, Amgen Inc, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Jones+LH%22">Jones LH</searchLink>; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ketter+N%22">Ketter N</searchLink>; Non-clinical Safety Science, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.<br /><searchLink fieldCode="AU" term="%22Lahoti+TS%22">Lahoti TS</searchLink>; Drug Safety Research & Evaluation, Takeda Development Center Americas, Inc., Cambridge, MA, USA.; Development Sciences, Atrium Therapeutics, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Loberg+LI%22">Loberg LI</searchLink>; Emerging Therapeutic Platforms, AbbVie, Inc., North Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Messmer+D%22">Messmer D</searchLink>; Nurix Therapeutics, San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22O'Lone+R%22">O'Lone R</searchLink>; Health & Environmental Sciences Institute (HESI), Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Pastoor+T%22">Pastoor T</searchLink>; Oerth Bio, Durham, NC, USA.<br /><searchLink fieldCode="AU" term="%22Pavkovic+M%22">Pavkovic M</searchLink>; Preclinical Development, Pharma R&D, Bayer AG, Wuppertal, Germany.<br /><searchLink fieldCode="AU" term="%22Pereira+Mouriès+L%22">Pereira Mouriès L</searchLink>; Health & Environmental Sciences Institute (HESI), Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Rankovic+Z%22">Rankovic Z</searchLink>; Institute of Cancer Research, London, Sutton, UK.<br /><searchLink fieldCode="AU" term="%22Rengarajan+A%22">Rengarajan A</searchLink>; Nonclinical Drug Safety, Merck & Co., Inc., West Point, PA, USA.<br /><searchLink fieldCode="AU" term="%22Vargesson+N%22">Vargesson N</searchLink>; Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, UK.<br /><searchLink fieldCode="AU" term="%22Vicart+A%22">Vicart A</searchLink>; Preclinical Safety, Biomedical Research, Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Wange+RL%22">Wange RL</searchLink>; Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.; Aclairo Pharmaceutical, Development Group, Inc., Sterling, VA, USA.<br /><searchLink fieldCode="AU" term="%22Yanochko-Hoffman+G%22">Yanochko-Hoffman G</searchLink>; Preclinical Sciences & Translational Safety, Johnson & Johnson, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Roberts+R%22">Roberts R</searchLink>; ApconiX Ltd. Alderley Park, Macclesfield, UK. ruth.roberts@apconix.com.; School of Biosciences, University of Birmingham, Edgbaston, UK. ruth.roberts@apconix.com.<br /><searchLink fieldCode="AU" term="%22Sidaway+J%22">Sidaway J</searchLink>; ApconiX Ltd. Alderley Park, Macclesfield, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101124171%22">Nature reviews. Drug discovery</searchLink> [Nat Rev Drug Discov] 2026 Apr 20. <i>Date of Electronic Publication: </i>2026 Apr 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101124171 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-1784 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214741776%22">14741776 </searchLink><i>NLM ISO Abbreviation: </i>Nat Rev Drug Discov <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42009768
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41573-026-01426-2
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Safety considerations for cereblon-recruiting targeted protein degraders.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Garside H
      – PersonEntity:
          Name:
            NameFull: Aslamkhan A
      – PersonEntity:
          Name:
            NameFull: Daniels DL
      – PersonEntity:
          Name:
            NameFull: Datta K
      – PersonEntity:
          Name:
            NameFull: Egebjerg M
      – PersonEntity:
          Name:
            NameFull: Hukkanen RR
      – PersonEntity:
          Name:
            NameFull: Jones LH
      – PersonEntity:
          Name:
            NameFull: Ketter N
      – PersonEntity:
          Name:
            NameFull: Lahoti TS
      – PersonEntity:
          Name:
            NameFull: Loberg LI
      – PersonEntity:
          Name:
            NameFull: Messmer D
      – PersonEntity:
          Name:
            NameFull: O'Lone R
      – PersonEntity:
          Name:
            NameFull: Pastoor T
      – PersonEntity:
          Name:
            NameFull: Pavkovic M
      – PersonEntity:
          Name:
            NameFull: Pereira Mouriès L
      – PersonEntity:
          Name:
            NameFull: Rankovic Z
      – PersonEntity:
          Name:
            NameFull: Rengarajan A
      – PersonEntity:
          Name:
            NameFull: Vargesson N
      – PersonEntity:
          Name:
            NameFull: Vicart A
      – PersonEntity:
          Name:
            NameFull: Wange RL
      – PersonEntity:
          Name:
            NameFull: Yanochko-Hoffman G
      – PersonEntity:
          Name:
            NameFull: Roberts R
      – PersonEntity:
          Name:
            NameFull: Sidaway J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 20
              M: 04
              Text: 2026 Apr 20
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1474-1784
          Titles:
            – TitleFull: Nature reviews. Drug discovery
              Type: main
ResultId 1